US Patent Issued to Regeneron Pharmaceuticals, Inhibrx Biosciences on Feb. 17 for "CD33 targeted immunotherapies" (Massachusetts, California Inventors)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,552,855, issued on Feb. 17, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.) and Inhibrx Biosciences Inc. (La Jolla, Calif.).

"CD33 targeted immunotherapies" was invented by Jordan Jarjour (Cambridge, Mass.), Mark Pogson (Cambridge, Mass.), Wai-Hang Leung (Cambridge, Mass.), Kyle Jones (La Jolla, Calif.), William Crago (La Jolla, Calif.), Angelica Sanabria (La Jolla, Calif.), Andrew Hollands (La Jolla, Calif.), Jacob Gano (La Jolla, Calif.), Milton Ma (La Jolla, Calif.), John C. Timmer (La Jolla, Calif.) and Brendan P. Eckelman (La Jolla, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides improved CD33 ...